A New York appeals court has upheld the state’s use of public funds to support marijuana dispensaries, rejecting a lawsuit arguing that financing businesses involved in federally prohibited marijuana sales violates federal law.
In a unanimous ruling issued October 29, the New York Supreme Court’s Appellate Division, Third Department, affirmed the dismissal of a lawsuit brought by the Cannabis Impact Prevention Coalition and several other plaintiffs. The lawsuit challenged state financing for dispensaries operated by social-equity licensees, arguing that the program conflicts with the federal Controlled Substances Act (CSA).
The dispute centers on New York’s Conditional Adult-Use Retail Dispensary (CAURD) program, established following the state’s legalization of recreational marijuana in 2021. In 2022, lawmakers authorized the Dormitory Authority of the State of New York to select an investment fund to help finance the development of dispensaries, including securing retail locations, constructing facilities and making necessary improvements.
The resulting New York Social Equity Cannabis Investment Fund was established as a public-private financing initiative of up to $200 million, including $50 million in state funding and up to $150 million in private investment. The program was designed to help individuals disproportionately affected by previous marijuana prohibition establish licensed retail businesses.
The plaintiffs argued that using state funds to facilitate marijuana distribution violates the CSA, which continues to prohibit marijuana activities covered by the lawsuit. They maintained that New York’s financing arrangements directly conflict with federal law and requested an injunction permanently blocking further expenditures.
However, the appeals court rejected that argument, finding that providing financial assistance to state-licensed marijuana businesses does not require anyone to violate federal law.
The judges emphasized that New York’s financing program does not provide immunity from federal prosecution or prevent federal authorities from enforcing federal marijuana restrictions.
“That funding does not require any person to engage in conduct prohibited by the CSA,” the court stated.
The ruling also cited an earlier decision involving the Cannabis Impact Prevention Coalition, in which the same appeals court rejected a federal preemption challenge to New York’s marijuana labeling, advertising and marketing regulations. In that case, the court determined that state marijuana regulations did not make compliance with federal law impossible or prevent federal enforcement.
Applying the same reasoning to the dispensary financing program, the judges concluded that the plaintiffs had failed to establish the type of conflict necessary for federal law to override state law.
The court acknowledged that the financing program is intended to facilitate the licensed distribution of marijuana, but found that this alone does not establish a violation of federal preemption principles.
The decision leaves intact a February 2025 ruling by an Albany County Supreme Court judge dismissing the lawsuit. It also allows the challenged financing arrangements to remain in place, although the ruling does not protect participating dispensaries from potential federal enforcement.
Related posts:

New York's Highest Court Takes Up Case That Could Affect Appeals of Past Marijuana Convictions

Federal Appeals Court Rejects Bid to Restore $31.8 Million Marijuana Verdict Against Curaleaf Subsid...








